作者: Jing Wang , Hong-kai Su , Hua-fu Zhao , Zhong-ping Chen , Shing-shun Tony To
DOI: 10.1016/J.BBRC.2015.07.148
关键词:
摘要: Gliomas are a common adult central nervous system tumor, and glioblastoma (GBM), which has poor prognosis, is the most lethal of all gliomas. The overall survival GBM patients only 12-14 months after diagnosis. With progress in precision personal medication, therapeutic options for various tumors have become gradually dependent on molecular profiles patients. one treatment response relies largely characteristics tumor. Therefore, awareness genetic background each patient will help decision-making regarding best strategy to use. In this review, novel classification gliomas based recent findings their introduced. Representative markers, such as IDH1 mutation, 1p19q co-deletion, MGMT promoter methylation EGFRvIII amplification, described. Furthermore, development non-coding RNAs omics studies briefly discussed. Finally, concept non-invasive detection that could facilitate both diagnosis monitoring presented. There no doubt use profiling by biomarkers indeed improve quality life